Health

STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/10/2026, 10:51:24 UTC.

Briefings

Eli Lilly announced a head-to-head study showing its investigational retatrutide drug outperformed Novo Nordisk's Ozempic in lowering blood sugar and weight loss for diabetics. The trial compared the highest dose of retatrutide against Ozempic, revealing a 2.2 percentage-point A1c reduction versus 1.8 percentage-points, and a 20.9% weight loss versus 9.4%. Results were based on participants who remained on treatment for 80 weeks.

Key points

• Eli Lilly's investigational drug retatrutide showed a 2.2 percentage-point reduction in A1c compared to Novo Nordisk's Ozempic in an 80-week head-to-head study.
• Participants on the highest dose of retatrutide lost 20.9% of their weight, significantly higher than the 9.4% loss observed with Ozempic.

Context

This competitive study between Eli Lilly and Novo Nordisk provides new data on diabetes treatment efficacy, with results based on participants who completed the 80-week trial period.

Limitations

Results are based only on participants who stayed on treatment for 80 weeks; the study compares highest doses only. No additional background context is supplied.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/10/2026, 10:53:07 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeibywi4dd5bkswl55ggvwanceeryfqzkiaretjpewhoxdi6uhfwvxu